You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
82 search results for: biologics
expert video
Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness
Rhinology
Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.
ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
Pulmonology
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.
ERS 2024 | Can Biologics Affect Airway Remodeling?
Pulmonology
Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.
EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma
Pulmonology
Join Professor Vibeke Backer for a presentation on clinical remission in asthma and achieving remission with biologics for patients with uncontrolled asthma.
What proportion of patients can achieve control in CRSwNP?
Rhinology
Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.
ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?
Pulmonology
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Sharon Dell highlights the available clinical biologic efficacy data in pediatric severe asthma, suggesting the potential for achieving clinical remission when added to an asthma management plan.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.